+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Effect of flutamide an anti androgen on stage d cancer of the prostate



Effect of flutamide an anti androgen on stage d cancer of the prostate



Clinical Pharmacology & Therapeutics 29(2): 256




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 028167531

Download citation: RISBibTeXText


Related references

Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen. International Journal of Urology 17(4): 337-345, 2010

Micellar delivery of flutamide via milk protein nanovehicles enhances its anti-tumor efficacy in androgen-dependent prostate cancer rat model. Pharmaceutical Research 30(10): 2654-2663, 2014

Androgen receptor expression in androgen-independent prostate cancer Relation to flutamide withdrawal. Proceedings of the American Association for Cancer Research Annual Meeting 37(0): 245, 1996

Effect of flutamide and flutamide plus castration on prostate size in patients with previously untreated prostate cancer. Urology 47(5): 713-718, 1996

Combination of resveratrol and antiandrogen flutamide has synergistic effect on androgen receptor inhibition in prostate cancer cells. Anticancer Research 31(10): 3323-3330, 2011

Comparative results of the variations in intra prostatic androgen levels and androgen receptors following pulpectomy with or without an anti androgen flutamide in the treatment of advanced prostatic cancer. Murphy, G P , Et Al (Ed ) Progress in Clinical And Biological Research, Vol 243a Prostate Cancer, Part A: Research, Endocrine Treatment, And Histopathology; Second International Symposium, Paris, France, June 16-18, 1986 Xl+586p Alan R Liss, Inc : New York, New York, Usa Illus 77-78, 1987

TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Research 66(22): 10658-10663, 2006

Clinical outcomes of anti-androgen withdrawal and subsequent alternative anti-androgen therapy for advanced prostate cancer following failure of initial maximum androgen blockade. Molecular and Clinical Oncology 4(5): 839-844, 2016

Renewed sensitivity to androgen and anti-androgen in androgen-independent prostate cancer cells through re-expression of androgen receptor by an IkappaB super-repressor. Journal of Urology 165(5 Supplement): 44, 2001

Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a Japanese perspective--the effect of primary androgen deprivation therapy on stage C prostate cancer. Bju International 99 Suppl 1: 10-2; Discussion 17-8, 2007

Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. American Journal of Medicine 98(4): 412-414, 1995

Anti-tumor effect of small interfering RNA targeting the androgen receptor in human androgen-independent prostate cancer cells. Biochemical and Biophysical Research Communications 391(1): 1075-1079, 2010

Leuprolide plus flutamide: combined androgen blockade in the treatment of advanced prostate cancer. Mount Sinai Journal of Medicine, New York 57(3): 171-173, 1990